Journal of Vaccine Research 2024, Vol.14, No.6, 297-306 http://medscipublisher.com/index.php/jvr 302 memory characteristics of influenza antigen-specific CD4+/CD8+ T cells. By monitoring activation markers such as CD69 and CD107a, this technology can precisely assess the quality of immune cells induced by vaccines. 6.2 Dimensions of immune efficacy evaluation The efficacy of vaccines is directly related to the intensity and persistence of T-cell responses. Data from FLU-v vaccinated individuals show that the number of specific immune cells peaks at 42 days and persists until 180 days. This long-acting response lays the foundation for anti-influenza protection (Oftung et al., 2022). It is worth noting that immune persistence is of greater clinical value than the initial response intensity. Multifunctional T cell populations (which secrete multiple cytokines simultaneously) are important indicators for evaluating the quality of vaccines. Clinical trials of plant-based vector vaccines have found that the multicytokine secretion ability of CD4+/CD8+ T cells can still be detected 6 months after vaccination. This multi-dimensional immune response significantly enhances the defense efficacy (Landry et al., 2014). 6.3 Analysis of core biomarkers The key indicators of immune protection are mainly reflected in two dimensions: dynamic proliferation and synergistic regulation. The proliferation marker Ki-67 can reflect the activation intensity of T cells in real time. Studies have shown that the expression level of Ki-67 in CD4+ T cells increased by 300% within 24 hours after vaccination, but rapidly dropped back to the baseline level after 72 hours. This pulsed activation pattern reveals the rapid mobilization mechanism of the immune system (Landry et al., 2014). The transient characteristics of this marker provide a quantitative basis for evaluating the onset speed of the vaccine. Another important type of indicator is the co-expression pattern of cytokines. The triple combination of interferon -γ, IL-17A and IL-21 has been confirmed to have a dual synergistic effect: it can not only activate the killing function of T cells, but also promote the maturation of B cell antibodies (Skibinski et al., 2018). By monitoring the concentration gradient changes of these immune signaling molecules, researchers can establish a multi-parameter prediction model for vaccine efficacy. 7 Clinical Progress and Challenges of Universal Influenza Vaccines 7.1 Latest updates on clinical trials Breakthroughs have been made in the clinical stage of global influenza vaccine research and development. The innovative vaccine H1N1/VN04 has demonstrated broad-spectrum protective effects in mouse and human experiments, achieving multi-virus strain defense by activating T lymphocyte immunity (Valkenburg et al., 2018). It is worth noting that influenza-specific CD4+ T cells can not only promote early antibody production but also enhance the memory function of CD8+ T cells, which provides a new direction for vaccine design. Schmidt's team (2021) further discovered that respiratory resident memory T cells (TRM) play a key role in cross-protection and advocated that T-cell targeting technology be adopted as the core strategy for universal vaccines. Compared with traditional vaccines that rely on antibodies, the new generation of T-cell vaccines shows unique advantages. Janssens et al. (2022) confirmed that vaccines developed for virus-conserved areas can establish a lasting immune barrier and effectively respond to seasonal epidemics and large-scale outbreaks. Verification by animal models shows that T-cell-mediated immune defense has broad-spectrum antiviral properties (Clemens et al., 2018). 7.2 Challenges in universal vaccine development This field still faces multiple technical bottlenecks: Firstly, the genetic diversity of human MHC molecules leads to individual differences in T-cell immune responses (Isakova-Sivak et al., 2021); Secondly, the uncertainty of the immune dominance pattern and the limitations of animal models affect the research progress. Furthermore, the key parameters of the independent protection mechanism of T cells (quantity threshold, tissue distribution, duration) remain to be clarified (Clemens et al., 2018). The current evaluation system overly relies on antibody detection indicators, which may underestimate the true efficacy of vaccines. Establishing a standardized T-cell response detection platform has become an urgent need for
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==